BR0214557A - regime de dosagem de eritropoietina para o tratamento de anemia - Google Patents

regime de dosagem de eritropoietina para o tratamento de anemia

Info

Publication number
BR0214557A
BR0214557A BRPI0214557-0A BR0214557A BR0214557A BR 0214557 A BR0214557 A BR 0214557A BR 0214557 A BR0214557 A BR 0214557A BR 0214557 A BR0214557 A BR 0214557A
Authority
BR
Brazil
Prior art keywords
erythropoietin
anemia
treatment
dosing regimen
dosage
Prior art date
Application number
BRPI0214557-0A
Other languages
English (en)
Inventor
Francis Farrell
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of BR0214557A publication Critical patent/BR0214557A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"REGIME DE DOSAGEM DE ERITROPOIETINA PARA O TRATAMENTO DE ANEMIA". A presente invenção provê um novo regime de dosagem de injeção subcutânea para eritropoietina para tratar anemia. O novo regime de tratamento com eritropoietina da presente invenção resulta em níveis de hemoglobina aumentados com dosagem menos freqüente.
BRPI0214557-0A 2001-11-28 2002-11-26 regime de dosagem de eritropoietina para o tratamento de anemia BR0214557A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33395801P 2001-11-28 2001-11-28
PCT/US2002/037982 WO2003045423A1 (en) 2001-11-28 2002-11-26 Erythropoietin dosing regimen for treating anemia

Publications (1)

Publication Number Publication Date
BR0214557A true BR0214557A (pt) 2006-06-06

Family

ID=23304949

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0214557-0A BR0214557A (pt) 2001-11-28 2002-11-26 regime de dosagem de eritropoietina para o tratamento de anemia

Country Status (9)

Country Link
US (1) US7232797B2 (pt)
EP (1) EP1461065A1 (pt)
JP (1) JP2005530678A (pt)
AU (1) AU2002357019A1 (pt)
BR (1) BR0214557A (pt)
CA (1) CA2468499A1 (pt)
MX (1) MXPA04005068A (pt)
NZ (1) NZ532988A (pt)
WO (1) WO2003045423A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US20050282751A1 (en) * 2004-03-19 2005-12-22 Ajinomoto Co., Inc. Therapeutic agent for renal anemia
US7879361B2 (en) * 2005-01-04 2011-02-01 Gp Medical, Inc. Nanoparticles for drug delivery
US8216994B2 (en) * 2009-11-09 2012-07-10 Ecolab Usa Inc. Phosphate functionalized alkyl polyglucosides used for enhanced food soil removal
TWI576091B (zh) * 2010-03-23 2017-04-01 費森尼斯醫療德國公司 造血作用刺激劑（ｅｓａ）效果之預測方法與裝置及其投予劑量之決定方法與裝置
WO2011163506A2 (en) 2010-06-23 2011-12-29 University Of Louisville Research Foundation, Inc. Methods and kits for predicting a response to an erythropoietic agent
PT2416154T (pt) * 2010-08-03 2017-08-09 Fresenius Medical Care Deutschland Gmbh Método e aparelhos para prever os efeitos de agentes estimulantes de eritropoiese (aee), e para determinar uma dose a ser administrada
EP2754076B1 (en) * 2011-09-08 2021-03-10 Fresenius Medical Care Holdings, Inc. System and method of modeling erythropoiesis and its management
WO2013049624A1 (en) 2011-09-30 2013-04-04 University Of Louisville Research Foundation, Inc. System and method for personalized dosing of pharmacologic agents
EP2895973B1 (en) 2012-09-14 2024-07-24 The University of Massachusetts Methods and devices for determining optimal agent dosages
JP2019532618A (ja) * 2016-07-12 2019-11-14 ヘキサル・アクチェンゲゼルシャフト 低アセチル化率シアル酸残基を有する糖タンパク質

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173067B1 (da) * 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US6153407A (en) 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
CN1057534C (zh) 1993-08-17 2000-10-18 柯瑞英-艾格公司 促红细胞生成素类似物
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
EP0964702B1 (en) 1996-08-02 2006-10-04 Ortho-McNeil Pharmaceutical, Inc. Polypeptides having a single covalently bound n-terminal water-soluble polymer
JP4541539B2 (ja) 1997-07-23 2010-09-08 ロシュ ダイアグノスティックス ゲーエムベーハー 内因性遺伝子活性化によるエリスロポエチンの製造
ES2208798T3 (es) 1997-09-01 2004-06-16 Aventis Pharma Deutschland Gmbh Eritropoyetina humana recombinante con un perfil de glicosilacion ventajoso.
DE69933216T2 (de) 1998-06-15 2007-09-20 GTC Biotherapeutics, Inc., Framingham Erythropoietin-analog-menschliches serum-albumin fusionsprotein
WO2000067776A1 (en) 1999-05-11 2000-11-16 Ortho-Mcneil Pharmaceuticals, Inc. Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration

Also Published As

Publication number Publication date
US20030134795A1 (en) 2003-07-17
MXPA04005068A (es) 2004-08-19
US7232797B2 (en) 2007-06-19
EP1461065A1 (en) 2004-09-29
JP2005530678A (ja) 2005-10-13
AU2002357019A1 (en) 2003-06-10
CA2468499A1 (en) 2003-06-05
WO2003045423A1 (en) 2003-06-05
NZ532988A (en) 2008-04-30

Similar Documents

Publication Publication Date Title
CY1120922T1 (el) Παραγωγα πυρρολιου ως φαρμακευτικοι παραγοντες
BE2012C005I2 (pt)
BRPI0313792B8 (pt) utilização de proteína de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
BR0214557A (pt) regime de dosagem de eritropoietina para o tratamento de anemia
TW200502385A (en) Modulation of forkhead box o1a expression
BRPI0411024A (pt) métodos para induzir a eritropoiese intensificada ou completa em um paciente, para tratar ou prevenir doenças, e para aumentar a produção da eritropoietina na presença de uma citocina em um paciente, uso de um composto, kit, e, composição farmacêutica
BR0313282A (pt) Composições de inibidor seletivo de ciclooxigenase-2 e um inibidor de anidrase carbÈnica para o tratamento de neoplasia
PT1039887E (pt) Metodos para o tratamento de neuro e nefro disturbios e de toxicidades terapeuticas usando compostos de aminotiol
BR0110573A (pt) Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização do composto e processo para o tratamento profilático ou terapêutico e para a preparação do composto
BRPI0407897A (pt) derivados de cianopiridina úteis no tratamento de cáncer e outros distúrbios
GT200100183A (es) Derivados de quinolina y quinazolina.
PT1195159E (pt) Combinacao terapeutica de ascorbato com lisina e arginina para prevencao e tratamento do cancro
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
CY1112397T1 (el) Συνδυασμενη θεραπεια για την αντιμετωπιση του καρκινου
DK0583421T3 (da) Substituerede dibenzoxazepinforbindelser, lægemidler og fremgangsmåder til anvendelse
MX2026001319A (es) Producto farmacologico para terapia enzimatica para el tratamiento de la homocistinuria
BR0111989A (pt) Peptìdeos, composições e processos para o tratamento de burkholderia cepacia
BR0316523A (pt) Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente
BR0207443A (pt) Método e forma de dosagem para o tratamento de tumores pela administração de tegafur, uracila, ácido folìnico, paclitaxel e carboplatina
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
BR0201862A (pt) Composições e métodos para tratar ou prevenir convulsões ou ataques apoplécticos
ATE341343T1 (de) Medizinische zusammensetzungen mit diuretischem und die insulinresistenz verbesserndem mittel
ATE554753T1 (de) 2,2'-dithio-bis(ethansulfonat) für den einsatz zur hemmung paclitaxel-induzierter abnormer thermoesthesia
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
DE60222383D1 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]